Also known as: Ozempic, Wegovy, Rybelsus
A long-acting GLP-1 receptor agonist. The most studied weight-loss drug of its class.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Mimics the gut hormone GLP-1. Slows stomach emptying, acts on appetite centers in the brain, and raises insulin only when glucose is high.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Fat loss & weight | A | Approved for this use or large randomized trials |
| Blood sugar & metabolic | A | Approved for this use or large randomized trials |
| Heart & circulation | A | Approved for this use or large randomized trials |
| Joint pain & inflammation | B | Human trials (smaller, mixed, or approved outside the US) |
| Stress, anxiety & mood | C | Limited human data, case series or practitioner reports |
At a glance
- Route
- Subcutaneous weekly; oral daily tablet
- Half-life
- About 7 days
Reported dosing
Weight (Wegovy): 0.25 mg weekly for 4 weeks, then 0.5, 1.0, 1.7 mg, up to 2.4 mg weekly, stepping up every 4 weeks. Diabetes (Ozempic): up to 2 mg weekly.
Timing: Same day each week, any time of day, with or without food.
Cycle: Used continuously. Most weight returns within a year of stopping (STEP 1 extension).
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Nausea, vomiting, constipation or diarrhea, worst during dose increases
- Gallstones and, rarely, pancreatitis
- Loss of lean mass along with fat; protein intake and resistance training help
- Low blood sugar when combined with insulin or sulfonylureas
Who should avoid it
- Personal or family history of medullary thyroid cancer or MEN2
- Pregnancy or planning pregnancy
- History of pancreatitis or severe gastroparesis
Often combined with
Often paired with resistance training and high protein intake to protect muscle.
Key findings
SELECT trial: 20% fewer heart attacks, strokes and cardiovascular deaths in people with obesity and heart disease. STEP 1: about 15% average weight loss at 68 weeks. Approved for liver disease (MASH) in 2025.
2026 update
Wegovy self-pay is $349 a month. The oral Wegovy pill was approved in Dec 2025 ($149 to $299 a month). EMA and MHRA added NAION, a rare optic-nerve injury (1 in 10,000 or fewer), to the label in 2025 to 2026. Counterfeit pens have been reported.
Where it is legal (Oct 2026)
| US | Prescription |
|---|---|
| Canada | Prescription |
| Mexico | Prescription |
| EU | Prescription |
Sources
Open Semaglutide in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.